Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Malignant Melanoma: Update Bulletin [July 2016]

Product Code:
Publication Date:
July 2016

Gain new KOL insights on the latest events happening in malignant melanoma (MM): Array BioPharma’s submission of a New Drug Application (NDA) for binimetinib to the US Food and Drug Administration (FDA) in advanced NRAS-mutant melanoma patients; the prospects for Incyte’s Phase III ECHO-301 study evaluating epacadostat, in combination with Merck & Co.'s Keytruda (pembrolizumab), as first-line treatment for patients with advanced or metastatic melanoma; and the views on Celldex Therapeutics’ Phase II data evaluating CDX-1401, a dendritic cell targeting NY-ESO-1-antibody fusion protein for immunotherapy, and CDX-301 (recombinant human Flt3 ligand) in patients with malignant melanoma.

Key Questions Answered in this Update Bulletin:

  • What do KOLs think about the NEMO trial data for binimetinib, and the product’s chances of success? 
  • How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?
  • How does Novartis’/Array BioPharma’s binimetinib/encorafenib, a combination being evaluated in the COLUMBUS trial, compare to existing BRAF/MEK therapies?
  • What do KOLs think of Incyte’s epacadostat and could the Phase III ECHO-301 study open up the oncology field for this IDO inhibitor/mAb combination?
  • Will the epacadostat/ pembrolizumab combination find a role in front-line treatment for advanced melanoma, or is it likely to be confined to the adjuvant setting?
  • How do KOLs view the data for CDX-1401/CDX-301 immunotherapy?
  • Is Celldex Therapeutics’ vaccine therapy likely to succeed where others have failed?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved